Tulane Educational Fund is a private company headquartered in the United States specializing in radio broadcasting stations.

Anthrogenesis, based in Cedar Knolls, New Jersey, is a biotherapeutics company that has developed proprietary methods for collecting, processing and storing stem cells and other valuable biomaterials derived from human placental tissue. Anthrogenesis is focused on developing and delivering therapies using stem cells sourced from human placental tissue to treat cancers and immunological, metabolic and inflammatory diseases. Anthrogenesis has demonstrated that the human placenta is an abundant source of biotherapies, including early stage stem cells and other biomaterials for organ and tissue repair. Anthrogenesis also operates Lifebank, a state-licensed blood bank that banks stem cell transplant units derived from placental tissue and in some cases, blood from the umbilical cord that is collected immediately after birth.

Omnio is a spin-off from Umeå University based on conceptual break through research on the wound healing properties of Plasminogen.

Omnio Healer AB is a company developing novel drug candidates based on a series of conceptual breakthroughs in inflammation research. This new, pro-inflammatory approach opens up completely new therapeutic strategies for wound healing and anti-infection. The company's lead drug candidate, aimed primarily at otological indications, has achieved promising preclinical results and will enter a clinical development program in late 2010.\nSince its foundation in 2006 Omnio Healer has assembled a management and development team. This includes scientists within the field, experienced product development professionals and active investors led by Karolinska Development AB, providing access to a network of biotechnology development resources. The company is based in Umeå, Sweden.

Fidia SpA designs, produces and distributes integrated milling systems, which is applied in the manufacturing of molds and dies for automotive industry and in aerospace field. It also provide solutions for the complete milling process, from the definition of the machining program to the finished product. The company was founded by Giuseppe Morfino in 1974 and is headquartered in San Mauro Torinese, Italy.

Mor Research Applications is the Technology Transfer Office of Clalit Health Services, the largest HMO in Israel, providing end-to-end technology transfer services. MOR helps inventors translate new ideas in the medical, pharmaceutical, diagnostics, medical IT, and biotechnology areas into products and solutions that benefit healthcare providers and patients.

Zeteo Tech, Inc. operates as a venture-backed biodefense and medical device company that develops revolutionary class of fieldable biological mass spectrometers. Its instruments identify airborne microbes, proteins and lipids, and can be used to screen for infectious disease and other bio-threats. The company was founded by Charles Call, Wayne A. Bryden and and James Carlini is headquartered in Sykesville, MA.

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. Eledon Pharmaceuticals was founded on March 26, 2004 and is headquartered in Irvine, CA.

Part of Universit��t des Saarlandes, Leibniz-Institut f��r Neue Materialien gGmbH (doing business as INM �� Leibniz-Institut f��r Neue Materialien gGmbH) is a company headquartered in Saarbruecken, Germany. The firm engages in research and development of materials. It was founded in 1987 by Herbert Gleiter. Eduard Arzt is currently the CEO of the company.

Unitika Ltd. engages in the polymer and functional materials business. It operates through the following business segments: Polymer, Functional Material, Fiber, and Others. The Polymer segment manufactures and sells plastic film, resin, and non-woven cloth. The Functional Material segment handles the manufacture and sale of glass fibers. The Fiber segment deals with the manufacture and sale of various fibers such as thread, cotton, and knitted fibers. The Others segment includes environmental business, medical business, lifestyle and wellness, and real estate businesses. The company was founded on June 19, 1889 and is headquartered in Osaka, Japan.

Shenzhen Tianrui Renjian Biotechnology Co., Ltd., established on 2012-07-16, Business scope includes general business items:R&D and technical consulting of biopharmaceuticals;Domestic Trade;Operating import and export business(None of the above is legal,Administrative regulations,The State Council decides to specify items that require pre-approval and prohibition).,The licensing program is:

Nobelpharma was founded in 2003, and in 2008 we obtained our first marketing approval for an ethical drug, NOBELZIN®. We now have marketing approvals for and sell 18 new drugs and one new medical device. In the pharmaceuticals industry, there are no companies of similar scale and age launching as many new drugs as we have. It is the pursuit of our unique product planning and research and development that has led to this achievement. We engage in the projects of "drugs and medical devices for unmet medical needs" which are critical but neglected. We chose not to carry out the time-consuming and costly basic researches. Instead, we conduct license negotiations and research activities focusing on patient needs and select the best possible candidates (new drug candidates) from outside our company. This is because we want to deliver the drugs and medical devices for unmet medical needs to the medical front as quickly as possible, for the benefit of the patients. Unique management strategy for

Part of Cook Group, Inc., Cook Biotech, Inc. is a company headquartered in West Lafayette, IN, that develops and manufactures medical products for tissue repair and regenerative medicine applications. The firm was founded in 1963.\nThe company says this about itself: Cook Biotech Inc. develops and manufactures medical products for tissue repair and regenerative medicine applications using proprietary extracellular matrix (ECM) technologies and processes. Cook Biotech products are marketed and distributed under several brand names, including Biodesign® and OASIS®. Cook Biotech collaborates with partners and distributors, including AxoGen Inc., Aziyo Biologics, Cook Medical Inc., Cormatrix, Katena Products Inc., Keystone Dental Inc., and Smith & Nephew Inc., to develop new products and provide technical support. Cook Biotech was established in 1995 and is affiliated with Cook Medical Holdings in Bloomington, Indiana. It is located in the Purdue Research Park in West Lafayette, Indiana.

Yissum is the technology transfer company of The Hebrew University of Jerusalem. Founded in 1964, it is the 3rd company of its kind ever created, and has a rich tradition of innovation and commercialization. Through our efforts to identify and create breakthrough scientific research at Hebrew University, we aspire to advance commercial solutions to the most pressing global challenges facing humanity. (Contact Tamir Huberman) Some of our well-known spin-off companies include Mobileye, Orcam, Collplant, Qlight, and Briefcam. Yissum’s business partners span the globe and include companies such as Novartis, Johnson & Johnson, Merck, Intel, Google, Boston Scientific, ICL and many more. Since its inception, Yissum has registered 10,000+ patents covering 2,800+ inventions; licensed 900 technologies and produced 130+ spin-off companies.

Hadasit is the technology transfer company of Hadassah Medical Center in Jerusalem. They transform the cutting-edge research coming out of Hadassah into marketable medical technologies. They turn ground-breaking ideas into viable products and services that can change the world and better humanity. For more than a century, Hadassah has set the standard of excellence for medical care and research in Israel. Their doctors and scientists are on the frontlines, uniquely positioned to pinpoint ever-evolving medical needs. Their experience and ingenuity has yielded new ideas with huge potential in all areas of medicine, including therapeutics, diagnostic medical devices, and digital health. More than half of all hospital research in Israel is conducted at Hadassah. Hadasit is Hadassah’s vehicle for commercialization of the intellectual property and R&D capabilities developed there. Hadasit holds exclusive rights to every innovation and invention emerging from Hadassah and they are dedicated to bringing these life-saving technologies to the general public.

Urumqi No. 1 People's Hospital is a private company headquartered in Wulumuqi, China, that provides healthcare services.

Beijing Shangdi New Century Biomedical Research Institute Co., Ltd., established on 1999-11-01, Business scope includes legal,Prohibited by regulations and national foreign investment industrial policies,Not allowed to operate;law,Projects that require approval according to laws and regulations and that are restricted by national foreign investment industrial policies,Do not operate without approval;law,The regulations do not provide for approval and the national foreign investment industry policy does not restrict operations,Independent choice of business projects,Carry out business activities.(The enterprise was2004year3moon30Currently a domestic enterprise,At2004year3moon30Change to a wholly foreign-owned enterprise in the future.)

Wenzhou Jiayi 3D Technology Co., Ltd., established on 2017-10-23, Business scope includes 3D technology,Technological Development of Numerical Control Technology,technical consulting,Technical Services;medical instruments,Scientific research on automation equipment(The above shall not engage in production,Processing business);automation equipment,CNC technology products,3DPrinters and Consumables,3D scanner,Computer hardware and software,electronic product(Does not include electronic publications)promotion of,maintain,Install;Corporate Image Planning,Cultural and artistic activities exchange planning;Medical Device Sales(The operating permit).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)